Dudley Robert Michael
Known title: Chief Executive OfficerCIK: 0001854161
Dudley Robert Michael's purchase track record
How the stock did after each of Dudley Robert Michael's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since May 27, 2022
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-92.6%
3 months: -63.1%
Beat the S&P 500
0%
median -99.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/28/2023 | RNAZ | $50K | -70.3% | -97.0% | +22.2% |
| 6/20/2023 | RNAZ | $49K | -80.1% | -94.2% | +8.6% |
| 6/9/2023 | RNAZ | $52K | -63.1% | -92.6% | +7.1% |
| 9/14/2022 | RNAZ | $23K | -60.3% | -69.7% | -1.4% |
| 5/27/2022 | RNAZ | $55K | -38.8% | -73.3% | -3.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNAZ | ▲ Buy | Open Market | 98,000 | $50K | 9/28/2023 | View on chart |
| RNAZ | ▲ Buy | Open Market | 12,000 | $32K | 6/21/2023 | View on chart |
| RNAZ | ▲ Buy | Open Market | 6,607 | $17K | 6/20/2023 | View on chart |
| RNAZ | ▲ Buy | Open Market | 19,000 | $52K | 6/9/2023 | View on chart |
| RNAZ | ▲ Buy | Open Market | 20,000 | $23K | 9/14/2022 | View on chart |
| RNAZ | ▲ Buy | Open Market | 2,000 | $4K | 5/31/2022 | View on chart |
| RNAZ | ▲ Buy | Open Market | 28,000 | $52K | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
TransCode Reports Phase 1a Data for TTX-MC138
TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.
TransCode Reports Phase 1a Data for TTX-MC138. TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.